Viralytics is focused on the development and commercialisation of oncolytic immunotherapies that harness the power of certain viruses to preferentially infect and kill cancer cells. Our lead product candidate is CAVATAKTM, a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21), now being evaluated in Phase 1 and 2 clinical trials. CAVATAK binds to specific receptor proteins highly expressed on a range of cancer cell types, and acts to destroy local as well as metastatic tumour cells through cell lysis and the potential generation of a specific immune response against the cancer cells. Through these selective mechanisms of action, our therapies are designed to provide greater tolerability and efficacy, offering hope on an improved quality of life to patients with cancers that are difficult to treat with current therapeutic approaches.
7 Nov 2014 Positive CAVATAKTM Combination Data Presented at 2014 Society for Immunotherapy of Cancer (SITC) Meeting
30 Sep 2014 CAVATAKTM Immunotherapy Combination Demonstrates Superior Anti-cancer Activity
© Viralytics Limited 2014
This information does not take your circumstances into account. Read the relevant ASX releases, financial reports and prospectuses before making an investment decision. Shares in Viralytics Limited, ABN 12 010 657 351, are traded on the Australian Stock Exchange (ASX:VLA) and on the over-the-counter market (OTC: VRACY).